Forte Biosciences 2025 loss widens on FB102 spend
Forte Biosciences reported a larger 2025 net loss as it ramped investment in lead drug FB102.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Forte Biosciences reported a larger 2025 net loss as it ramped investment in lead drug FB102. Net loss was $69.4 million versus $35.5 million in 2024, or $(4.71) per share versus $(12.17).
Research and development expenses rose to $58.2 million from $21.2 million, mainly from FB102 phase 2 celiac and phase 1b vitiligo and alopecia trials. General and administrative expenses declined to $12.4 million from $15.4 million, helped by lower professional and legal costs.
Forte ended 2025 with $77.0 million in cash and cash equivalents. As of December 31, 2025, there were 12.9 million common shares and 4.9 million prefunded warrants outstanding. The company highlighted multiple FB102 clinical readouts expected in 2026 across celiac disease, vitiligo and alopecia areata.
8-K Event Classification
Key Figures
Key Terms
phase 2 celiac disease study medical
phase 1b clinical trials medical
monoclonal antibody medical
IND regulatory
forward-looking statements regulatory
Earnings Snapshot
Company highlighted 2026 topline data readouts for FB102 in celiac disease, vitiligo and alopecia areata.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Forte Biosciences (FBRX) perform financially in 2025?
How much did Forte Biosciences spend on R&D for FB102 in 2025?
What was Forte Biosciences’ cash position at the end of 2025?
How did Forte Biosciences’ general and administrative expenses change in 2025?
What upcoming FB102 clinical milestones did Forte Biosciences highlight for 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
| |
||||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s Telephone Number, Including Area Code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Financial Statements and Exhibits. |
On March 31, 2026, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit |
Description | |
| 99.1 | Press Release dated March 31, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FORTE BIOSCIENCES, INC. | ||||||
| Date: April 1, 2026 | By: | /s/ Antony Riley | ||||
| Antony Riley Chief Financial Officer | ||||||
Exhibit 99.1
FORTE BIOSCIENCES, INC. ANNOUNCES 2025 RESULTS AND PROVIDES UPDATE
DALLAS, TX – MARCH 31, 2026 – Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and provided a business update.
“The clinical development for FB102 continues to progress well with important readouts in 2026.” said Forte Biosciences CEO Paul Wagner, PhD. “The topline results from our phase 2 celiac disease study is expected in 2026. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which we reported in June 2025, we look forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The FB102 phase 1b vitiligo clinical study is expected to have topline results in 1H 2026 and the alopecia areata phase 1b data readout is expected in 2026. This will be a very eventful year and further highlight FB102’s potential to address the significant unmet medical needs across multiple indications representing multi-billion dollar potential market opportunities.”
2025 Operating Results
Research and development expenses were $58.2 million for the year ended December 31, 2025, compared to $21.2 million during the same period in 2024. The increase was primarily due to an increase of $36 million in manufacturing and clinical expenses related to FB102 for our Phase 2 clinical trial for celiac disease and Phase 1b clinical trials for vitiligo and alopecia areata, an increase of $0.4 million in discovery work, and an increase of $1.9 million in personnel-related expenses due to an increase in headcount, partially offset by a decrease of $1.5 million in preclinical expenses as a result of toxicology work performed in 2024.
Our research and development expenses may increase as we continue to advance FB102 through a celiac Phase 2 trial including a U.S. arm as a result of the FDA approving our IND, multiple Phase 1b clinical trials and if we pursue additional autoimmune indications.
General and administrative expenses were $12.4 million for the year ended December 31, 2025 compared to $15.4 million for the same period in 2024. The decrease was primarily due to decreases in professional and legal advisory fees, including litigation and settlement expenses, of $6.1 million, partially offset by an increase of $3.0 million in personnel-related expenses, including additional non-cash stock-based compensation of $2.5 million.
Our general and administrative expenses may fluctuate in the future due to fluctuations in professional and advisory fees as we build out our infrastructure to advance FB102 through a Phase 2 trial, multiple Phase 1b clinical trials and if we pursue additional autoimmune indications.
Net losses per share were $(4.71) and $(12.17) for the year ended December 31, 2025 and 2024, respectively.
Forte ended the fourth quarter of 2025 with $77.0 million in cash and cash equivalents. There are 12.9 million shares of common stock and 4.9 million prefunded warrants outstanding as of December 31, 2025.
Forte Biosciences, Inc.
Consolidated Balance Sheets
(in thousands, except share and par value data)
| December 31, 2025 |
December 31, 2024 |
|||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 76,957 | $ | 22,244 | ||||
| Short-term investment |
— | 36,121 | ||||||
| Prepaid expenses and other current assets |
3,632 | 2,981 | ||||||
|
|
|
|
|
|||||
| Total current assets |
80,589 | 61,346 | ||||||
| Property and equipment, net |
129 | 77 | ||||||
| Other assets |
2,061 | 138 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 82,779 | $ | 61,561 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 9,989 | $ | 4,879 | ||||
| Accrued liabilities |
10,762 | 4,202 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
20,751 | 9,081 | ||||||
| Income tax payable |
1,037 | — | ||||||
|
|
|
|
|
|||||
| Total liabilities |
21,788 | 9,081 | ||||||
| Commitments and contingencies (Note 6) |
||||||||
| Stockholders’ equity: |
||||||||
| Common stock, $0.001 par value: 200,000,000 share, authorized as of December 31, 2025 and December 31, 2024; 12,948,308 and 6,393 ,323 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively |
13 | 6 | ||||||
| Additional paid-in capital |
284,348 | 206,461 | ||||||
| Accumulated other comprehensive income |
3 | 11 | ||||||
| Accumulated deficit |
(223,373 | ) | (153,998 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
60,991 | 52,480 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 82,779 | $ | 61,561 | ||||
|
|
|
|
|
|||||
Forte Biosciences, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: |
||||||||
| Research and development |
$ | 57,647 | $ | 20,714 | ||||
| Research and development - related party |
600 | 479 | ||||||
| General and administrative |
12,410 | 15,409 | ||||||
|
|
|
|
|
|||||
| Total operating expenses |
70,657 | 36,602 | ||||||
|
|
|
|
|
|||||
| Loss from operations |
(70,657 | ) | (36,602 | ) | ||||
| Interest income |
2,715 | 1,314 | ||||||
| Other expense, net |
(396 | ) | (190 | ) | ||||
|
|
|
|
|
|||||
| Total other income, net |
2,319 | 1,124 | ||||||
|
|
|
|
|
|||||
| Net loss before taxes |
(68,338 | ) | (35,478 | ) | ||||
| Income tax expense |
1,037 | — | ||||||
|
|
|
|
|
|||||
| Net loss |
$ | (69,375 | ) | $ | (35,478 | ) | ||
|
|
|
|
|
|||||
| Per share information: |
||||||||
| Net loss per share - basic and diluted |
$ | (4.71 | ) | $ | (12.17 | ) | ||
| Weighted average share, and pre-funded warrants outstanding, basic and diluted |
14,717,734 | 2,915,894 | ||||||
| Comprehensive loss: |
||||||||
| Net loss |
$ | (69,375 | ) | $ | (35,478 | ) | ||
| Unrealized (loss) gain on available-for-sale securities, net |
(8 | ) | 7 | |||||
|
|
|
|
|
|||||
| Comprehensive loss |
$ | (69,383 | ) | $ | (35,471 | ) | ||
|
|
|
|
|
|||||
Additional details on Forte’s full year 2025 financial results can be found in Forte’s Form 10-K as filed with the SEC on March 31, 2026. You can also find more information in the investor relations section of Forte’s website at www.fortebiorx.com.
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
Forward-Looking Statements
Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. Forward-looking statements include statements regarding the Company’s beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, expectations for patient enrollment and timing of clinical data readouts. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte’s ability to obtain sufficient additional capital to continue to advance Forte’s product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte’s product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials, including the timing of the completion of the Company’s patient-based trials; the risk that results from preclinical and any interim result of our ongoing clinical trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte’s business and operating results is contained in Forte’s Annual Report on Forms 10-K filed on March 31, 2026, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
| Contact: |
||
| LifeSci Advisors | Forte Biosciences, Inc. | |
| Mike Moyer, Managing Director | Paul Wagner, CEO | |
| mmoyer@lifesciadvisors.com | investors@fortebiorx.com | |